We are live on ! Find out more
PJP icon

Invesco Pharmaceuticals ETF
PJP

93 hedge funds and large institutions have $59M invested in Invesco Pharmaceuticals ETF in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

14% more capital invested

Capital invested by funds: $51.8M → $59M (+$7.22M)

1% more funds holding

Funds holding: 92 → 93 (+1)

0.05% less ownership

Funds ownership: 22.28% → 22.23% (-0.05%)

17% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 23

Holders
93
Holders Change
+1
Holders Change %
+1.09%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
19
Reduced
23
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$730K
2
Goldman Sachs
Goldman Sachs
New York
+$635K
3
LPL Financial
LPL Financial
California
+$510K
4
Citadel Advisors
Citadel Advisors
Florida
+$477K
5
WI
WBI Investments
New Jersey
+$472K

Top Sellers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$799K
2
Wells Fargo
Wells Fargo
California
-$651K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$545K
4
TRCT
Tower Research Capital (TRC)
New York
-$408K
5
SWGC
Summit Wealth Group (Colorado)
Colorado
-$366K
Name Holding Trade Value Shares
Change 		Change in
Stake
PNC Financial Services Group
51
PNC Financial Services Group
Pennsylvania
$94.8K – – –
Rockefeller Capital Management
52
Rockefeller Capital Management
New York
$94.5K +$89.4K +1,021 New
JP Morgan Chase
53
JP Morgan Chase
New York
$92.9K -$15.9K -182 -15%
Fidelity Investments
54
Fidelity Investments
Massachusetts
$89.2K +$5.78K +66 +7%
Bank of Montreal
55
Bank of Montreal
Ontario, Canada
$57.3K – – –
NSIM
56
North Star Investment Management
Illinois
$55.5K – – –
AWM
57
AE Wealth Management
Kansas
$54.6K -$11.1K -127 -18%
BCWM
58
Bartlett & Co Wealth Management
Ohio
$53.1K – – –
NEWAS
59
N.E.W. Advisory Services
Wisconsin
$42.2K +$88 +1 +0.2%
HI
60
Harbour Investments
Wisconsin
$39.7K – – –
GI
61
GAMMA Investing
California
$39.6K – – –
FFL
62
Financial Freedom LLC
Ohio
$35.7K +$88 +1 +0.3%
DFA
63
DHJJ Financial Advisors
Illinois
$32.1K +$88 +1 +0.3%
IA
64
IFP Advisors
Florida
$31K – – –
ACA
65
Aptus Capital Advisors
Alabama
$18.9K – – –
MCM
66
MAI Capital Management
Ohio
$18.3K – – –
Comerica Bank
67
Comerica Bank
Texas
$17.6K – – –
RF
68
Rossby Financial
Florida
$15.3K – – –
ASN
69
Advisory Services Network
Georgia
$15.3K +$14.4K +165 New
HB
70
Horizon Bancorp
Indiana
$14K – – –
HIA
71
Harbor Investment Advisory
Maryland
$13.9K – – –
Carson Wealth (CWM LLC)
72
Carson Wealth (CWM LLC)
Nebraska
$12K +$11.8K +135 New
FDCDDQ
73
Federation des caisses Desjardins du Quebec
Quebec, Canada
$11.9K – – –
MMCM
74
Murphy & Mullick Capital Management
New York
$11K – – –
HCM
75
Hollencrest Capital Management
California
$9.34K – – –
1 2
3
4

PJP Hedge Fund Activity: Q3 2025 in Review

93 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q3 2025, worth a combined $59M — up 14% from $51.8M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new PJP positions and 7 closed out — a net gain of 1 holder — while 19 added to existing stakes and 23 trimmed.

The largest buyer was Ameriprise, adding an estimated $730K. The largest seller was BNP Paribas Financial Markets, exiting entirely with an estimated $799K sold.

  • 93 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q3 2025, up from 92 in Q2 2025.
  • Funds reported $59M of Invesco Pharmaceuticals ETF stock for Q3 2025, up 14% quarter-over-quarter.
  • 8 funds opened new Invesco Pharmaceuticals ETF positions in Q3 2025 and 7 closed out, a net change of +1 holder.
  • The largest Invesco Pharmaceuticals ETF buyer in Q3 2025 was Ameriprise, an estimated $730K added.
  • The largest Invesco Pharmaceuticals ETF seller in Q3 2025 was BNP Paribas Financial Markets, an estimated $799K sold.

Based on aggregated 13F filings for Q3 2025.